Patent · US Active

Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene

US9255250B2 · kind B2 · utility

39Cited by

34References

5Claims

0Family size

Assignees

Sangamo Biosciences, Inc. · US
THE CHILDREN'S HOSPITAL OF PHILADELPHIA · US

Inventors

Philip D. Gregory · Richmond, US
Katherine A. High · Yeadon, US

Key dates

Filing date	Dec 4, 2013
Grant date	Feb 9, 2016
Priority date	—
Expiry date	Dec 4, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2035/124
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Cells and methods of using these cells for expressing a transgene expressing a protein that is aberrantly expressed in a metabolic disorders from a safe harbor locus.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.